Benzinga | Aug 19, 2021 08:16AM EDT

Adagene Inks Third Cancer Trial Collaboration With Merck

* Adagene Inc (NASDAQ:ADAG) has entered into a third clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE:MRK).

* The agreement includes an open-label, dose-escalation, and expansion clinical study of ADG106 combined with Merck's Keytruda (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies.

* ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb developed to treat advanced solid tumors and non-Hodgkin's lymphoma.

* Related: Adagene To Test Its Anti-CTLA-4 Antibodies In Combination With Keytruda In Solid Tumors.

* Price Action: ADAG shares closed 4.02% lower at $17.80 on Wednesday.